
Browsing restrictions can be lifted for a fee.
-
Apollomics, inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
No related data records
The most recent financial report for Apollomics, inc. (APLMW) covers the period of 2024Q2 and was published on 2024/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APLMW's short-term business performance and financial health. For the latest updates on APLMW's earnings releases, visit this page regularly.
According to the latest financial report, Apollomics, inc. (APLMW) reported an Operating Profit of -12.57M with an Operating Margin of -1,299.43% this period, representing a growth of 2.09% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Apollomics, inc. (APLMW) announced revenue of 967.5K, with a Year-Over-Year growth rate of 296.52%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, Apollomics, inc. (APLMW) held Total Cash and Cash Equivalents of 9.77M, accounting for 0.75 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
According to the past four quarterly reports, Apollomics, inc. (APLMW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Apollomics, inc. (APLMW)'s Free Cash Flow (FCF) for the period is -8.01M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 34.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.